We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat
Read MoreHide Full Article
Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) reported second-quarter 2021 earnings on Aug 5. The quarterly results have managed to impress investors as the stock moved up 1.5% to close at $17.39 on Aug 6.
The company’s delivered adjusted earnings per share (“EPS”) of 23 cents in the second quarter of 2021, up 35.3% year over year. The figure surpassed the Zacks Consensus Estimate by 27.8%.
GAAP EPS for the quarter was 15 cents a share against the year-earlier loss of 5 cents per share.
Revenues in Detail
Allscripts registered revenues of $373.7 million in the second quarter, up 1.2% year over year. The figure surpassed the Zacks Consensus Estimate by 0.3%.
For second-quarter 2021, bookings came in at $180 million, up 9.8% from the prior-year quarter, driven by robust demand across the company’s full solutions portfolio.
Segment Details
In the quarter under review, revenues at the Software delivery, support and maintenance segment amounted to $219.6 million on a reported basis, down 1.8% from the year-ago quarter's tally.
The Client services segment’s revenues totaled $154.1 million, up 5.8% from the year-ago quarter's figure.
Allscripts Healthcare Solutions, Inc. Price, Consensus and EPS Surprise
In the quarter under review, Allscripts’ gross profit rose 8.8% to $182 million. Gross margin expanded 340 basis points (bps) to 48.6%.
Selling, general & administrative expenses fell 28% to $79.1 million. Research and development expenses went up 11.3% year over year to $51.2 million. Adjusted operating expenses of $130 million decreased 16.4% year over year.
Adjusted operating profit totaled $51 million, reflecting a 363.1% surge from the prior-year quarter. Adjusted operating margin in the second quarter expanded a huge 1075 bps to 13.8%.
Financial Position
Allscripts exited the second quarter of 2021 with cash and cash equivalents of $229.3 million compared with $513.4 million at the end of the first quarter. Long-term debt at the end of the second quarter of 2021 was $421.3 million compared with $169.4 million at the end of the first quarter.
Cumulative net cash provided by operating activities (continuing operations) at the end of the second quarter was $125.1 million compared to cumulative net cash used in operating activities (continuing operations) of $19.7 million a year ago.
2021 Guidance
Allscripts reaffirmed its prior current-year revenue view at $1.50 billion, at par with the Zacks Consensus Estimate.
Our Take
Allscripts exited the second quarter of 2021 with better-than-expected results. The year-over-year uptick in both top and bottom lines, along with surge in total bookings during the reported quarter, is impressive. Revenues from the Client services segment also rose during the quarter, which is encouraging. Over the past few months, Allscripts has entered into a slew of collaborations, raising our confidence on the stock.
Management is also upbeat about its strong domestic and global pipeline for health systems, which further buoys our optimism on the stock. The company also expects to benefit from investments it has made to deliver Sunrise as the platform of health, which will be delivered in the cloud through its partnership with Microsoft. Expansion of both margins is another positive.
On the flip side, Allscripts witnessed a decline in its Software delivery unit revenues during the second quarter. The company also experienced residual delays in closing some new deals, particularly with large health systems market and in international regions where recovery from the pandemic has been more uneven, raising our apprehension about the continued pandemic-led impacts. Additionally, Allscripts is exposed to integration risks. Intense competition in the niche space is also a concern.
Zacks Rank and Other Key Picks
Allscripts currently has a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space that have announced their quarterly results are Encompass Health Corporation (EHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
Encompass Health, carrying a Zacks Rank #2, reported second-quarter 2021 adjusted EPS of $1.17, which beat the Zacks Consensus Estimate by 15.8%. Second-quarter revenues of $1.3 billion outpaced the consensus mark by 1.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Second-quarter revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Bio-Rad reported second-quarter 2021 adjusted EPS of $3.54, surpassing the Zacks Consensus Estimate by 86.3%. Revenues of $715.9 million surpassed the Zacks Consensus Estimate by 17.3%. It currently sports a Zacks Rank #1.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat
Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) reported second-quarter 2021 earnings on Aug 5. The quarterly results have managed to impress investors as the stock moved up 1.5% to close at $17.39 on Aug 6.
The company’s delivered adjusted earnings per share (“EPS”) of 23 cents in the second quarter of 2021, up 35.3% year over year. The figure surpassed the Zacks Consensus Estimate by 27.8%.
GAAP EPS for the quarter was 15 cents a share against the year-earlier loss of 5 cents per share.
Revenues in Detail
Allscripts registered revenues of $373.7 million in the second quarter, up 1.2% year over year. The figure surpassed the Zacks Consensus Estimate by 0.3%.
For second-quarter 2021, bookings came in at $180 million, up 9.8% from the prior-year quarter, driven by robust demand across the company’s full solutions portfolio.
Segment Details
In the quarter under review, revenues at the Software delivery, support and maintenance segment amounted to $219.6 million on a reported basis, down 1.8% from the year-ago quarter's tally.
The Client services segment’s revenues totaled $154.1 million, up 5.8% from the year-ago quarter's figure.
Allscripts Healthcare Solutions, Inc. Price, Consensus and EPS Surprise
Allscripts Healthcare Solutions, Inc. price-consensus-eps-surprise-chart | Allscripts Healthcare Solutions, Inc. Quote
Margin Trend
In the quarter under review, Allscripts’ gross profit rose 8.8% to $182 million. Gross margin expanded 340 basis points (bps) to 48.6%.
Selling, general & administrative expenses fell 28% to $79.1 million. Research and development expenses went up 11.3% year over year to $51.2 million. Adjusted operating expenses of $130 million decreased 16.4% year over year.
Adjusted operating profit totaled $51 million, reflecting a 363.1% surge from the prior-year quarter. Adjusted operating margin in the second quarter expanded a huge 1075 bps to 13.8%.
Financial Position
Allscripts exited the second quarter of 2021 with cash and cash equivalents of $229.3 million compared with $513.4 million at the end of the first quarter. Long-term debt at the end of the second quarter of 2021 was $421.3 million compared with $169.4 million at the end of the first quarter.
Cumulative net cash provided by operating activities (continuing operations) at the end of the second quarter was $125.1 million compared to cumulative net cash used in operating activities (continuing operations) of $19.7 million a year ago.
2021 Guidance
Allscripts reaffirmed its prior current-year revenue view at $1.50 billion, at par with the Zacks Consensus Estimate.
Our Take
Allscripts exited the second quarter of 2021 with better-than-expected results. The year-over-year uptick in both top and bottom lines, along with surge in total bookings during the reported quarter, is impressive. Revenues from the Client services segment also rose during the quarter, which is encouraging. Over the past few months, Allscripts has entered into a slew of collaborations, raising our confidence on the stock.
Management is also upbeat about its strong domestic and global pipeline for health systems, which further buoys our optimism on the stock. The company also expects to benefit from investments it has made to deliver Sunrise as the platform of health, which will be delivered in the cloud through its partnership with Microsoft. Expansion of both margins is another positive.
On the flip side, Allscripts witnessed a decline in its Software delivery unit revenues during the second quarter. The company also experienced residual delays in closing some new deals, particularly with large health systems market and in international regions where recovery from the pandemic has been more uneven, raising our apprehension about the continued pandemic-led impacts. Additionally, Allscripts is exposed to integration risks. Intense competition in the niche space is also a concern.
Zacks Rank and Other Key Picks
Allscripts currently has a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space that have announced their quarterly results are Encompass Health Corporation (EHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
Encompass Health, carrying a Zacks Rank #2, reported second-quarter 2021 adjusted EPS of $1.17, which beat the Zacks Consensus Estimate by 15.8%. Second-quarter revenues of $1.3 billion outpaced the consensus mark by 1.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Second-quarter revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Bio-Rad reported second-quarter 2021 adjusted EPS of $3.54, surpassing the Zacks Consensus Estimate by 86.3%. Revenues of $715.9 million surpassed the Zacks Consensus Estimate by 17.3%. It currently sports a Zacks Rank #1.